PNI、NLR在醋酸阿比特龙联合泼尼松治疗转移去势抵抗前列腺癌病人的初始疗效和预后预测中的意义

孙峰; 李红霞; 陶陶; 朱婷; 李玉芝; 葛磊; 许国胜; 朱敬波; 孙峰; 李红霞; 陶陶; 朱婷; 李玉芝; 葛磊; 许国胜; 朱敬波

doi:10.13898/j.cnki.issn.1000-2200.2022.07.004

[1]

CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115. doi: 10.3322/caac.21338

[2]

曾浩, 种铁, 贺大林, 等. 去势抵抗型前列腺癌最新指南解读暨中国西部专家共识[J]. 现代泌尿外科杂志, 2017, 20(2): 85. doi: 10.3969/j.issn.1009-8291.2017.02.002

[3]

闫传武, 赵江. 术前外周血血小板/淋巴细胞比值与前列腺癌患者临床病理特征及根治术后生存时间的相关性分析[J]. 国际泌尿系统杂志, 2019, 39(1): 5. doi: 10.3760/cma.j.issn.1673-4416.2019.01.002

[4]

方晓, 郭建功, 黄金明, 等, 预后营养指数预测转移性去势抵抗前列腺癌患者阿比特龙初始耐药和预后[J]. 上海交通大学学报(医学版), 2019, 39(3): 316.

[5]

SUN Y, ZOU Q, SUN Z, et al. Abiraterone acetate for metastatic castrationresistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study[J]. Int J Urol, 2016, 23(5): 404. doi: 10.1111/iju.13051

[6]

RYAN CJ, SMITH MR, FIZAZI K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol, 2015, 16(2): 152.

[7]

BEER TM, ARMSTRONG AJ, RATHKOPF DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med, 2014, 371(5): 424.

[8]

PARKER C, NILSSON S, HEINRICH D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med, 2013, 369(3): 213. doi: 10.1056/NEJMoa1213755

[9]

UEDA Y, MATSUBARA N, TABATA KI, et al. Prostate-specific antigen flare phenomenon induced by abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer[J]. Clin Genitourin Cancer, 2017, 15(2): 320.

[10]

FAN L, WANG Y, CHENFEI C, et al. Chromogranin A and neurone-speciflc enolase variations during the flrst 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer[J]. BJU Int, 2017, 120(2): 226.

[11]

陶丹, 郭莲怡. NLR、PLR、MPV预测结直肠腺瘤性息肉和结直肠癌的临床意义[J]. 胃肠病学, 2020, 25(3): 162.

[12]

王水莲, 杨芳. 预后营养指数对癌症患者预后的临床意义[J]. 现代肿瘤学, 2019, 27(6): 184.

[13]

刘涛, 王辉, 王杰, 等. 术前中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对肾透明细胞癌的预后评估价值[J]. 临床泌尿外科杂志, 2021, 36(1): 7.

[14]

贾王强, 倪红谚, 袁龙. 外周血炎症细胞因子在结直肠癌预后中的研究进展[J]. 癌症进展, 2020, 18(15): 1522.

[15]

徐翠芳, 翟艳慧, 张崇阳. 姑息性干预对晚期恶性肿瘤患者生活质量及癌因性疲乏的影响[J]. 癌症进展, 2019, 17(22): 2721.

[16]

杨瑞娜, 袁小志, 任婧, 等. 晚期肿瘤患者营养风险及影响因素的研究[J]. 现代肿瘤医学, 2021, 29(12): 2130.

[17]

Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part II and III[J]. Esophagus, 2017, 14(1): 37.

[18]

FU H, ZHENG J, CAI J, et al. Systemic immune-inflammation index(SII) is useful to predict survival outcomes in patients after liver transplantation for hepatocellular carcinoma within hangzhou criteria[J]. Cell Physiol Biochem, 2018, 47(1): 293.

[19]

韩克松, 张帆, 李翠玲, 等. 结直肠癌患者中性粒细胞淋巴细胞比值和T淋巴细胞CD69变化的意义[J]. 中国中西医结合外科杂志, 2021, 27(2): 263.

[20]

中国抗癌协会泌尿肿瘤专业委员会. 中国去势抵抗性前列腺癌诊治专家共识[J]. 中华外科杂志, 2016, 54(7): 481.

[21]

SCHER HI, HALABI S, TANNOCK I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group[J]. J Clin Oncol, 2008, 26(7): 1148.

[22]

ANGELERGUES A, MAILLET D, FLECHON A, et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer[J]. Eur J Cancer, 2014, 50(9): 1602.

[23]

RYAN CJ, SMITH MR, FIZAZI K, et al. Abriaterone acetate plus prenisone versus placebo plus prednisone in chemotherapy -naive men with metastatic castration-resistant prostate cancer(COU-AA-302): final overall survival analysis of a randomised, double -blind, placebocontrolled phase 3 study[J]. Lancet Oncol, 2015, 16(2): 152.

[24]

李俊, 杜鸿, 熊国兵, 等. 去势抵抗性前列腺癌患者使用醋酸阿比特龙治疗后发生前列腺特异性抗原闪烁现象的相关因素[J]. 临床与病理杂志, 2018, 38(6): 1228.

[25]

BURGIO SL, CONTEDUCA V, RUDNAS B, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer[J]. Clin Genitourin Cancer, 2015, 13(1): 39.

[26]

NARMALA SK, BOULMAY BC. PSA flare after initiation of abiraterone acetate[J]. J Community Support Oncol, 2014, 12(5): 191.

[27]

OKADA S, SHIMADA J, TERAMUKAI S, et al. Risk stratification according to the prognostic nutritional index for predicting postoperative complications after lung cancer surgery[J]. Ann Surg Oncol, 2018, 25(5): 1254.

[28]

胡小剑, 郑亮, 张志刚, 等. 前列腺癌根治术患者治疗前后血小板/淋巴细胞比值变化及其与预后相关性分析[J]. 实用癌症杂志, 2020, 35(9): 1558.

[29]

赵雅文, 董頔, 薛茜文, 等. 术前外周血中NLR、PLR、LMR与早期宫颈癌患者预后的相关性研究[J]. 新疆医科大学学报, 2020, 43(8): 997.

[30]

高军, 宋伟杰, 刘祥虎, 等. 系统免疫炎症指数对初诊前列腺癌患者骨转移的预测价值[J]. 中华泌尿外科杂志, 2021, 42(10): 752.